This review examines fluoroquinolone resistance in Salmonella and Campylobacter, suggesting urgent changes are needed to mitigate public health risks.
Key Points
Fluoroquinolone resistance limits treatment options for human infections caused by Salmonella and Campylobacter.
Resistance prevalence is high in poultry, particularly in South Korea and China, with notable rates against ciprofloxacin and nalidixic acid.
The review discusses genetic mutations and mechanisms driving fluoroquinolone resistance, including chromosomal mutations and plasmid-mediated resistance genes.
A One Health approach is vital, promoting stronger regulations and alternative treatments to combat antimicrobial resistance threats.